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Abstract
Opioids are the mainstay of pain treatment in cancer. In the course of disease many patients will experience
increase of pain intensity and hence need an increase of the opioid dose. However, in some situations, when
for example the other treatment of pain is effective, the dose of opioids could and should be decreased or
even discontinued. Many patients continue on the opioids because it is unclear how and when to discontinue
them. We present the case of a patient treated for his pain with opioids. Opioids were responsible for vivid
delirium, probably exacerbating subclinical dementia. Treatment with steroid injections allowed to decrease
and later discontinuation of opioids with a clear gain in lucidity and cognitive functioning by the patient. We
propose the guidelines how and when to wean patients from the opioids. Buprenorphine and clonidine, but
possibly also gabapentin may play a role in the prevention and pharmacological treatment of the symptoms
of abstinence.
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Introduction
Opioids continue to be the mainstay for pain
relief in palliative care [1, 2]. They are usually used
in combination with other drugs and their dose
should always be titrated to the effect. When the
pain is under control with other modalities the
dose of opioids can and should be decreased or
sometimes even discontinued. Patients may also
sometimes wish to discontinue opioids, most of-
ten due to their annoying adverse effects. Also it
could be the case that patients want to get off
opioids due to the fear of addiction and/or de-
pendence. However, in many instances patients
with advanced disease will be continued on opio-
ids even though they do not require them any
more, simply for the sake of convenience, due,
primarily to concerns relating to adverse with-
drawal effects. Discontinuation of opioids may
induce pain, a condition defined as opioid induced
hyperalgesia, for a short period of time which
affirms to the patients and their doctors in the
conviction that they certainly need opioids [3–5].
This can result in unnecessary long term adverse
effects and considerable costs.
The guidelines for initiating opioid treatment are
well recognised and accessible; however there is no
consistent guidance for stopping the treatment. The
major concern with stopping opioid use is the with-
drawal syndrome that can develop within hours [5].
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The symptoms are not necessarily life threatening,
but can be very distressing, especially within the
sensitive settings of Palliative Care. Signs and symp-
toms of opioid withdrawal are those of sympa-
thetic over activity, and include tachycardia, tac-
hypnea, irritability, gastrointestinal symptoms,
vomiting, diarrhoea, abdominal cramps, insomnia,
anxiety, muscle spasms, and skin hyperalgesia. Un-
recognised, these symptoms may lead to the con-
clusion that the patient is again in pain and needs
recommencing of opioids.
Issues to consider are the time-frame of how
acutely the opioid treatment is to be discontinued
and also to take into account the individual case.
The goal should be to allow the patient to be opi-
oid free as quickly as possible with the least effects
of withdrawal or precipitation of any other condi-
tions. It would be difficult to set a given time frame
as factors such as age, prognosis, comorbidity, kind
of drug, duration and dose used and the patient’s
psychological status all need to be taken into ac-
count. There is probably no point to discontinue
opioids in somebody who is in his last weeks of life.
To illustrate the issue we want to present the
following case.
Mr A. was an 82 years old widowed man. He
was a retired military officer and his hobby was
to take care of retired greyhounds. He was well
cared by his daughter Jane (60) who lived next
door to him. Jane was single and partially dis-
abled as she has had poliomyelitis in her child-
hood and walked with a stick. Mr A. was diag-
nosed with locally advanced prostate cancer two
years before. There were no metastases and he
was treated with transurethral resection and cur-
ative radiotherapy to the prostate. After this treat-
ment he recovered fully and was able to function
alone at home. His prostate specific antigen (PSA)
initially increased, then dropped to the normal
values after radiotherapy. Eight months before
there was one abnormal high PSA value which
prompted his urologic surgeon to commence with
hormonal therapy. The bone scan repeatedly did
not reveal any hot-spots and the next readings of
the PSA were again normal. He continued on hor-
monal therapy but started to forget things. He
was sometimes agitated, especially in the evening.
His GP requested formal assessment for his de-
mentia as he expected that he will need a place-
ment in a psychogeriatric nursing home. This as-
sessment revealed mild dementia. Two months
before, he started to complain of pain in his low-
er back which did not respond to paracetamol
and NSAIDs. He was started on oral morphine
which was titrated to 30 mg bd and later changed
to fentanyl patches 25 and a week later to 50
mcg/hour. His pain was better controlled with this
treatment but still present, urging him to use the
oral morphine rescue doses of 10 mg, sometimes
3–5 times a day. He became also constipated and
struggled with his laxatives as he was terrified by
the idea of soiling the floor before reaching the
bathroom. He was not sleeping well, was agitat-
ed at night and still suffering the pain. He was
admitted for pain control to our hospice but need-
ed to be discharged because of aggression and
difficulties with the nursing staff. His daughter
did not want to admit him to the psychogeriatric
nursing home and took him back home. The con-
sultant (ZZ) visited him at home. He still appeared
to have a normal PSA and no signs of bone me-
tastases. He suffered from severe localised pain
at his iliac crest on the right side [6]. There were
three trigger points corresponding to the upper
cluneal nerve, cutaneous branch of the iliohypo-
gastric nerve and cutaneous branch of the sub-
costal XII nerve crossing the iliac crest. The three
sites were injected with bupivacaine and methyl-
prednisolone. The next day he was free of pain,
but much more confused. The fentanyl patch was
decreased to 25 mcg/hour and later swapped to
buprenorphine patches 20 mcg/hour. As he was
still without pain a week later, the dose was again
decreased to 10 and a week later to 5 mcg/hour.
Seven days after commencing him on buprenor-
phine 5 mcg/hour the patch was removed. He was
prescribed clonidine 0.1 mg tablets to be taken in
case of withdrawal symptoms, but he never used
them. He recovered fully after this and could stay
at home for another seven months. He was not
confused and the injections were repeated regu-
larly every 3 months until his death because of
massive stroke.
Discussion
Patients with dementia are particularly sensitive
to opioids [7]. Even small doses of these drugs may
totally deregulate them; make them confused and
sometimes aggressive. Obviously the pain should be
treated effectively and when needed with opioids.
However, particular effort should be taken to inten-
sify all non-opioid pain treatments to avoid drug
toxicity. Radiotherapy to painful bone metastases,
nerve blocks, and also the addition of pregabalin/
gabapentin to the treatment regime are just some
examples of such treatment. They all may result in a
decreased need of opioids and in some cases opioids
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can and should be fully discontinued. There is a scar-
city in the literature on weaning patients from opio-
ids, other than non-cancer opioid addicts.
Buprenorphine is an opioid with a high affinity
for opioid receptors. It has a partial agonist action
on the mu receptor and antagonistic effect on the
kappa receptor [8]. The affinity to both of these
receptors is high and buprenorphine potentially may
displace agonists from opioid receptors. Buprenor-
phine is used as a potent opioid analgesic in cancer
care [8–10] but can also be used as a drug of choice
in weaning patients addicted to opioids [11, 12].
The drug is slowly dissociating from the receptors
providing their continuous occupation with less than
maximal stimulation (partial agonism). This results
is a marked reduction in craving and other with-
drawal symptoms.
In clinical trials, buprenorphine has been found
to be more effective than clonidine [13]. Due to it
being a partial agonist rather than a full agonist, it is
safer to titrate down the dose more rapidly than
normal opioids. The slow dissociation of buprenor-
phine from the opioid receptors causes fewer with-
drawal symptoms on discontinuation. Recommen-
dations for buprenorphine treatment are presented
in Table 1.
Buprenorphine is available as a transdermal patch
in strengths of 5, 10 and 20 mg/h (Butrans) and 35,
52.5 and 70 mg/h (Transtec). The ideal medication
for transdermal administration should be highly li-
pophilic, potent and of low molecular weight for
ease of crossing the skin barrier [15]. Buprenorphine
meets all of these requirements.
Preliminary data from a survey of 3,255 patients
with chronic pain who had used a transdermal bu-
prenorphine product indicated that the incidence
of side effects was relatively low compared to other
opioids [16]. Long-term use of buprenorphine ad-
ministered as a transdermal patch (mean exposure
time 234 days, range 1–609 days) in approximately
400 patients with chronic pain in a clinical trial
showed no unexpected safety concerns [17]. Also
the dose of the drug remained very stable in com-
parison to what is known about other opioids.
Table 1.  Recommendations for buprenorphine treatment
Try to reduce the dose of original opioid as much as possible;
Swap patient from the last dose of original opioid to buprenorphine pathches using the equianalgesic dose tables [14];
Decrease the dose of buprenorphine patch once per week, decreasing it by 10 and later 5 mcg/hour;
Have clonidine 0.1 mg tablets “stand by” when the last patch is taken off;
The length of this process depends on how long the original opioid was used. The shorter this period was, the shorter
weaning off can be.
In the palliative care setting the transdermal
patch is much more advantageous over sublingual
therapies for a number of reasons. Patches provide
smoother, more continuous drug delivery, offering
steadier plasma levels of the opioid, and can have
less side-effects. With the patch being more patient
and carer friendly it can lead to better compliance.
Patients in Palliative Care tend to be frail and strug-
gle with medication and therefore a patch can pro-
vide ease of delivery.
The risk of lethal overdose on buprenorphine in
an opioid tolerant individual is less than that asso-
ciated with the use of other opioid medications.
This is due to the ceiling effect concerning the respi-
ratory depression but not analgesia [18].
Before buprenorphine patches, withdrawal
symptoms were treated with clonidine [19, 20]. Oral
clonidine 0.1–0.2 mg 4–6 hours as needed or by
transdermal patch (Clonidine transdermal 0.1 mg/
24 hour patch which provides 0.1 mg a day for 7
days) can be used to treat autonomic hyperactivity
symptoms.
Clonidine is a centrally-acting a-adrenergic re-
ceptor agonist. It selectively stimulates receptors in
the brain that monitor catecholamine levels in the
blood. These receptors close a negative feedback
loop that begins with sympathetic nerves from the
brain that controls the production of catecholamines
in the adrenal medulla. Clonidine causes the brain
to reduce its signals to the adrenal medulla, which
in turn lowers catecholamine production. The result
is a reduction in sympathetic activity causing a low-
ered heart rate and blood pressure, with side ef-
fects of dry mouth and fatigue. If clonidine is sud-
denly withdrawn the sympathetic nervous system
will revert to producing high levels of catechola-
mines, potentially causing a rebound reaction. This
is relevant to the treatment of hypertension with
clonidine but can be avoided by slowly withdraw-
ing treatment.
The major drawbacks of clonidine therapy are the
adverse effects: hypotension and dry mouth. Mea-
surement of blood pressure prior to commencing ther-
apy in patients with advanced disease is necessary. 
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In the recent years gabapentin and probably also
pregabalin emerged as a drug able to control the
withdrawal symptoms [21, 22]. There is only little
experience with these drugs in this context, but be-
cause of their frequent use in palliative care, poten-
tially, they may play an important role.
Other agents should be considered if required
and their use depends on the withdrawal symp-
toms that arise:
— diphenoxylate/atropine or loperamide to treat
acute diarrhoea;
— hydroxyzine for anxiety and sleep problems;
— trazodone, zolpidem, temazepam. Used for
anxiety, depressive illness, requiring and seda-
tion;
— dicycloverine hydrochloride for gastrointestinal
disorders;
— non steroid-anty-inflammatory drugs (NSAID’s)
for pain relief.
Conclusion
Currently there are no standard protocols for dis-
continuing opioids in Palliative Care due to the fact
that this is an uncommon practice. However, some
guidelines can be extrapolated from other disciplines.
Regardless of the reason for the discontinuation, the
plan must be individualised to each patient’s needs.
Close follow-up and psychosocial support are essen-
tial. Buprenorphine is an established, effective and
safe medication for use in the treatment of opioid
dependence and with its unique pharmacological
profile it can, in theory, be used in limiting adverse
effects of withdrawal from long term high dose opi-
oid therapy in Palliative Care, thus making it a safer
and steadier process for the patient.
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